Prognostic Value of Initial Bone Marrow Disease Detection by Multiparameter Flow Cytometry in Children with Neuroblastoma

Overview

Journal J Cancer Res Clin Oncol

Specialty Oncology

Date 2019 Jan 4

PMID 30603901

Citations 8

Authors

Alexander Popov

Alexander Druy

Egor Shorikov

Tatiana Verzhbitskaya

Alexander Solodovnikov

Leonid Saveliev

Godelieve A M Tytgat

Grigory Tsaur

Larisa Fechina

Affiliations

Soon will be listed here.

Abstract

Purpose: Multicolor flow cytometry (MFC) is widely available, fast and has an easy-to perform approach for finding neuroblastoma (NB) cells among normal bone marrow (BM) hematopoietic cells. Aim of the study was to investigate prognostic significance of initial MFC tumor cells' detection in BM of children with NB.

Methods: 51 patients (24 boys and 27 girls) aged from 6 days to 15 years (median age 1 year 3 months) with NB were included in the study. BM samples at the time of diagnosis were obtained from 2 to 5 aspiration sites per patient. CD45(-)CD56(+)CD81(+)GD2(+)-cells were evaluated by MFC.

Results: NB cells were detected in BM by FC more frequently compared to conventional cytomorphology (49.0% and 29.4% patients, respectively, р = 0.043). Patients with NB cells detected in BM by MFC had significantly worse event-free survival and cumulative incidence of relapse/progression [0.24(0.08) and 0.60(0.10), respectively] compared to children with negative result of immunophenotyping [0.85(0.07) and 0.12(0.06), respectively, p < 0.001 in both cases]. BM involvement detection by MFC maintained its prognostic significance in various patients groups. In multivariate analysis, immunophenotyping proved to be an independent prognostic factor when analyzed jointly with other NB risk factors. In 42 patients BM involvement was also studied by RQ-PCR for PHOX2B and TH genes expression. Within groups of patients divided by RQ-PCR positivity, MFC-positivity retained prognostic significance.

Conclusions: Thus flow cytometric BM involvement detection has very strong prognostic impact even stronger than RQ-PCR. It could be used in combination with other parameters for the treatment strategy choice in patients with NB.

Citing Articles

Comparison of Bone Marrow Biopsy and Flow Cytometry in Demonstrating Bone Marrow Metastasis of Neuroblastoma.

Arslantas E, Aycicek A, Ozkara S, Ozkan Karagenc A, Tekgunduz S, Yildirgan D Diagnostics (Basel). 2025; 14(24.

PMID: 39767137 PMC: 11727105. DOI: 10.3390/diagnostics14242776.

Flow cytometry of bone marrow aspirates from neuroblastoma patients is a highly sensitive technique for quantification of low-level neuroblastoma.

Jain N, Sattar S, Inglott S, Burchill S, Fisher J, Serban A F1000Res. 2022; 10:947.

PMID: 35186272 PMC: 8825949. DOI: 10.12688/f1000research.53133.2.

Flow Cytometry Immunophenotyping for Diagnostic Orientation and Classification of Pediatric Cancer Based on the EuroFlow Solid Tumor Orientation Tube (STOT).

Ferreira-Facio C, Botafogo V, Ferrao P, Canellas M, Milito C, Romano S Cancers (Basel). 2021; 13(19).

PMID: 34638431 PMC: 8508207. DOI: 10.3390/cancers13194945.

Comparison of three different methods to detect bone marrow involvement in patients with neuroblastoma.

Schriegel F, Taschner-Mandl S, Bernkopf M, Grunwald U, Siebert N, Ambros P J Cancer Res Clin Oncol. 2021; 148(10):2581-2588.

PMID: 34623519 PMC: 9470647. DOI: 10.1007/s00432-021-03780-7.

The Significance of Histopathologic Assessment in Bone Marrow Disease in Neuroblastoma.

Ekmekci S, Ince D, Olgun N, Ozer E Turk Patoloji Derg. 2021; 38(2):99-105.

PMID: 34558657 PMC: 9999680. DOI: 10.5146/tjpath.2021.01556.

References

Hartmann O, Valteau-Couanet D, Vassal G, Lapierre V, Brugieres L, Delgado R . Prognostic factors in metastatic neuroblastoma in patients over 1 year of age treated with high-dose chemotherapy and stem cell transplantation: a multivariate analysis in 218 patients treated in a single institution. Bone Marrow Transplant. 1999; 23(8):789-95. DOI: 10.1038/sj.bmt.1701737. View

Cotterill S, Pearson A, Pritchard J, Foot A, Roald B, Kohler J . Clinical prognostic factors in 1277 patients with neuroblastoma: results of The European Neuroblastoma Study Group 'Survey' 1982-1992. Eur J Cancer. 2000; 36(7):901-8. DOI: 10.1016/s0959-8049(00)00058-7. View

Cheung I, Cheung N . Quantitation of marrow disease in neuroblastoma by real-time reverse transcription-PCR. Clin Cancer Res. 2001; 7(6):1698-705. View

Warzynski M, Graham D, Axtell R, Higgins J, Hammers Y . Flow cytometric immunophenotyping test for staging/monitoring neuroblastoma patients. Cytometry. 2002; 50(6):298-304. DOI: 10.1002/cyto.10159. View

Trager C, Kogner P, Lindskog M, Ponthan F, Kullman A, Kagedal B . Quantitative analysis of tyrosine hydroxylase mRNA for sensitive detection of neuroblastoma cells in blood and bone marrow. Clin Chem. 2003; 49(1):104-12. DOI: 10.1373/49.1.104. View

Tsang K, Li C, Tsoi W, Leung Y, Shing M, Chik K . Detection of micrometastasis of neuroblastoma to bone marrow and tumor dissemination to hematopoietic autografts using flow cytometry and reverse transcriptase-polymerase chain reaction. Cancer. 2003; 97(11):2887-97. DOI: 10.1002/cncr.11389. View

Swerts K, De Moerloose B, Dhooge C, Brichard B, Benoit Y, Laureys G . Detection of residual neuroblastoma cells in bone marrow: comparison of flow cytometry with immunocytochemistry. Cytometry B Clin Cytom. 2004; 61(1):9-19. DOI: 10.1002/cyto.b.20019. View

Warzynski M, Roys J, Peterson J, DeLa Vega H . Availability of conjugated ganglioside GD2 monoclonal antibody. Cytometry B Clin Cytom. 2005; 65(1):42-3. DOI: 10.1002/cyto.b.20054. View

Okcu M, Wang R, Bueso-Ramos C, Schober W, Weidner D, Andrassy R . Flow cytometry and fluorescence in situ hybridization to detect residual neuroblastoma cells in bone marrow. Pediatr Blood Cancer. 2005; 45(6):787-95. DOI: 10.1002/pbc.20428. View

10.

Ifversen M, Kagedal B, Christensen L, Rechnitzer C, Petersen B, Heilmann C . Comparison of immunocytochemistry, real-time quantitative RT-PCR and flow cytometry for detection of minimal residual disease in neuroblastoma. Int J Oncol. 2005; 27(1):121-9. View

11.

Bomken S, Redfern K, Wood K, Reid M, Tweddle D . Limitations in the ability of NB84 to detect metastatic neuroblastoma cells in bone marrow. J Clin Pathol. 2006; 59(9):927-9. PMC: 1860465. DOI: 10.1136/jcp.2005.035444. View

12.

Bozzi F, Gambirasio F, Luksch R, Collini P, Brando B, Fossati-Bellani F . Detecting CD56+/NB84+/CD45- immunophenotype in the bone marrow of patients with metastatic neuroblastoma using flow cytometry. Anticancer Res. 2006; 26(5A):3281-7. View

13.

Corrias M, Parodi S, Haupt R, Lacitignola L, Negri F, Sementa A . Detection of GD2-positive cells in bone marrow samples and survival of patients with localised neuroblastoma. Br J Cancer. 2008; 98(2):263-9. PMC: 2361437. DOI: 10.1038/sj.bjc.6604179. View

14.

Bozzi F, Collini P, Aiello A, Barzano E, Gambirasio F, Podda M . Flow cytometric phenotype of rhabdomyosarcoma bone marrow metastatic cells and its implication in differential diagnosis with neuroblastoma. Anticancer Res. 2008; 28(3A):1565-9. View

15.

Stutterheim J, Gerritsen A, Zappeij-Kannegieter L, Kleijn I, Dee R, Hooft L . PHOX2B is a novel and specific marker for minimal residual disease testing in neuroblastoma. J Clin Oncol. 2008; 26(33):5443-9. DOI: 10.1200/JCO.2007.13.6531. View

16.

Monclair T, Brodeur G, Ambros P, Brisse H, Cecchetto G, Holmes K . The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report. J Clin Oncol. 2008; 27(2):298-303. PMC: 2650389. DOI: 10.1200/JCO.2008.16.6876. View

17.

Gautam U, Srinivasan R, Rajwanshi A, Bansal D, Marwaha R . Comparative evaluation of flow-cytometric immunophenotyping and immunocytochemistry in the categorization of malignant small round cell tumors in fine-needle aspiration cytologic specimens. Cancer. 2008; 114(6):494-503. DOI: 10.1002/cncr.23948. View

18.

Beiske K, Burchill S, Cheung I, Hiyama E, Seeger R, Cohn S . Consensus criteria for sensitive detection of minimal neuroblastoma cells in bone marrow, blood and stem cell preparations by immunocytology and QRT-PCR: recommendations by the International Neuroblastoma Risk Group Task Force. Br J Cancer. 2009; 100(10):1627-37. PMC: 2696761. DOI: 10.1038/sj.bjc.6605029. View

19.

Stutterheim J, Gerritsen A, Zappeij-Kannegieter L, Yalcin B, Dee R, van Noesel M . Detecting minimal residual disease in neuroblastoma: the superiority of a panel of real-time quantitative PCR markers. Clin Chem. 2009; 55(7):1316-26. DOI: 10.1373/clinchem.2008.117945. View

20.

Corrias M, Haupt R, Carlini B, Cappelli E, Giardino S, Tripodi G . Multiple target molecular monitoring of bone marrow and peripheral blood samples from patients with localized neuroblastoma and healthy donors. Pediatr Blood Cancer. 2011; 58(1):43-9. DOI: 10.1002/pbc.22960. View